In "The X Change Rate," award-winning drag queen, entertainer and TV personality Monét X Change brings her signature wit, heart and style to BUILD Series. Trans activist Peppermint joined Monét to have a conversation about what she's been up to.
In "The X Change Rate," award-winning drag queen, entertainer and TV personality Monét X Change brings her signature wit, heart and style to BUILD Series. Trans activist Peppermint joined Monét to have a conversation about what she's been up to.
WisdomTree Issuer plc – Daily Fund Prices 25-November -20 WisdomTree Artificial Intelligence UCITS ETF - USD Acc25/11/2020IE00BDVPNG133791541USD202,563,684.7353.4252WisdomTree AT1 CoCo Bond UCITS ETF – USD25/11/2020IE00BZ0XVF52481081USD50,011,706.86103.9569WisdomTree AT1 CoCo Bond UCITS ETF – EUR Hedged25/11/2020IE00BFNNN236249036EUR25,992,505.19104.3725WisdomTree AT1 CoCo Bond UCITS ETF – GBP Hedged25/11/2020IE00BFNNN45934640GBP3,659,519.41105.6443WisdomTree AT1 CoCo Bond UCITS ETF – USD Acc25/11/2020IE00BZ0XVG6942463USD4,987,032.47117.4442WisdomTree AT1 CoCo Bond UCITS ETF – USD Hedged25/11/2020IE00BFNNN01217006USD1,885,462.70110.8704WisdomTree Battery Solutions UCITS ETF - USD Acc25/11/2020IE00BKLF1R751632534USD61,958,329.1737.9522WisdomTree Cloud Computing UCITS ETF - USD Acc25/11/2020IE00BJGWQN728523000USD399,200,999.4246.8381WisdomTree Emerging Markets Equity Income UCITS ETF25/11/2020IE00BQQ3Q0672583191USD37,140,094.1614.3776WisdomTree Emerging Markets Equity Income UCITS ETF Acc25/11/2020IE00BDF12W49190558USD3,789,819.0619.888WisdomTree Emerging Markets Small Cap Dividend UCITS ETF25/11/2020IE00BQZJBM261505000USD25,941,161.4817.2367WisdomTree Enhanced Commodity UCITS ETF – CHF Hedged Acc25/11/2020IE00BG88WL21160000CHF1,572,703.349.8294WisdomTree Enhanced Commodity UCITS ETF – EUR Hedged Acc25/11/2020IE00BG88WG771575000EUR14,444,462.699.1711WisdomTree Enhanced Commodity UCITS ETF – GBP Hedged Acc25/11/2020IE00BG88WH84575000GBP5,366,882.229.3337WisdomTree Enhanced Commodity UCITS ETF - USD25/11/2020IE00BZ1GHD37900000USD8,943,827.479.9376WisdomTree Enhanced Commodity UCITS ETF - USD Acc25/11/2020IE00BYMLZY747200000USD74,197,263.3310.3052WisdomTree EUR Aggregate Bond Enhanced Yield UCITS ETF – EUR25/11/2020IE00BD49R91272683EUR4,044,265.5455.6425WisdomTree EUR Aggregate Bond Enhanced Yield UCITS ETF – EUR Acc25/11/2020IE00BD49RB3952399EUR2,974,774.2856.7716WisdomTree EUR Government Bond Enhanced Yield UCITS ETF25/11/2020IE00BD49RJ1519908EUR1,136,867.1757.106WisdomTree EUR Government Bond Enhanced Yield UCITS ETF – EUR Acc25/11/2020IE00BD49RK2040000EUR2,328,014.2858.2004WisdomTree Europe Equity Income UCITS ETF25/11/2020IE00BQZJBX312032717EUR21,600,814.5210.6266WisdomTree Europe Equity Income UCITS ETF Acc25/11/2020IE00BDF16007352386EUR4,657,986.7213.2184WisdomTree Europe Equity UCITS ETF - CHF Hedged Acc25/11/2020IE00BYQCZT117703CHF132,816.2017.2421WisdomTree Europe Equity UCITS ETF - EUR Acc25/11/2020IE00BYQCZX56269545EUR4,735,711.6717.5693WisdomTree Europe Equity UCITS ETF - GBP Hedged25/11/2020IE00BYQCZQ89211454GBP2,337,956.0611.0566WisdomTree Europe Equity UCITS ETF - USD Hedged25/11/2020IE00BVXBH1631154076USD21,178,935.4418.3514WisdomTree Europe Equity UCITS ETF - USD Hedged Acc25/11/2020IE00BYQCZP723073523USD66,134,642.1421.5175WisdomTree Europe Small Cap Dividend UCITS ETF25/11/2020IE00BQZJC5271789262EUR28,597,687.7415.983WisdomTree Europe Small Cap Dividend UCITS ETF Acc25/11/2020IE00BDF16114262191EUR3,851,970.3114.6915WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR25/11/2020IE00BZ56SY76595193EUR10,289,876.7717.2883WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR Acc25/11/2020IE00BZ56TQ67777010EUR15,282,532.8419.6684WisdomTree Global Quality Dividend Growth UCITS ETF - USD25/11/2020IE00BZ56RN96171204USD4,580,931.3326.7572WisdomTree Global Quality Dividend Growth UCITS ETF - USD Acc25/11/2020IE00BZ56SW521636843USD47,198,709.7728.8352WisdomTree Japan Equity UCITS ETF - CHF Hedged Acc25/11/2020IE00BYQCZL3585650CHF1,572,038.0818.3542WisdomTree Japan Equity UCITS ETF - EUR Hedged Acc25/11/2020IE00BYQCZJ13201551EUR3,164,242.2615.6995WisdomTree Japan Equity UCITS ETF - GBP Hedged25/11/2020IE00BYQCZF7489539GBP909,056.8210.1526WisdomTree Japan Equity UCITS ETF - JPY Acc25/11/2020IE00BYQCZN58189960USD3,942,273.2620.7532WisdomTree Japan Equity UCITS ETF - USD Hedged25/11/2020IE00BVXC48541334109USD21,408,753.4516.0472WisdomTree Japan Equity UCITS ETF - USD Hedged Acc25/11/2020IE00BYQCZD50575675USD10,515,696.5818.2667WisdomTree UK Equity Income UCITS ETF25/11/2020IE00BYPGTJ261660000GBP6,853,990.244.1289WisdomTree US Equity Income UCITS ETF25/11/2020IE00BQZJBQ631129894USD21,116,789.9318.6892WisdomTree US Equity Income UCITS ETF - EUR Hedged Acc25/11/2020IE00BD6RZW238073EUR132,009.1416.3519WisdomTree US Equity Income UCITS ETF - GBP Hedged Acc25/11/2020IE00BD6RZZ53379189GBP5,562,162.7014.6686WisdomTree US Equity Income UCITS ETF Acc25/11/2020IE00BD6RZT931417277USD28,011,649.9919.7644WisdomTree US Quality Dividend Growth UCITS ETF - USD25/11/2020IE00BZ56RD98410031USD11,047,610.0026.9434WisdomTree US Quality Dividend Growth UCITS ETF - USD Acc25/11/2020IE00BZ56RG201907064USD55,156,164.0528.922WisdomTree USD Floating Rate Treasury Bond UCITS ETF - USD25/11/2020IE00BJFN5P6326000USD1,304,081.1650.157WisdomTree USD Floating Rate Treasury Bond UCITS ETF - USD Acc25/11/2020IE00BJJYYX67333822USD17,025,776.3951.0026
Save on All-Clad deals at the Black Friday & Cyber Monday 2020 sale, together with the best pots, pans, cookware sets & more savings
The best camera lens deals for Black Friday & Cyber Monday 2020, featuring Canon, Tamron, Nikon, and Sony discounts
Diplomats like to remain neutral but Nanaia Mahuta let the veil slip a little when a winner was declared in the U.S. election by tweeting a smiley-face emoji. Mahuta, the first indigenous Maori woman to be appointed New Zealand's foreign affairs minister, suppresses a real-life smile when asked about it.
Germany has extended its partial coronavirus lockdown until at least December 20, meaning cinemas in the European major will not resume operations before that date. It is also possible, German Chancellor Angela Merkel said, that restrictions could continue into January. A re-evaluation is due to take place on December 15. Warner Bros’ Wonder Woman 1984 […]
I'm so jealous
Dublin, Nov. 26, 2020 (GLOBE NEWSWIRE) -- The "Chromatography Resins Market Size, Share & Trends Analysis Report By Product (Natural, Synthetic), By Technique (Ion exchange, Affinity, Hydrophobic Interaction), By End Use, By Region, And Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering. The global chromatography resins market size is anticipated to reach USD 3.5 billion by 2027, expanding at a CAGR of 7.8%The growth in the market can be attributed to increasing demand for therapeutic antibodies for the treatment of patients. In addition, expanding end-use applications due to continuous innovation are expected to propel market growth in the near future.Extensive research and development activities in the chromatography resin industry has triggered the production of new resin products, which have better productivity in comparison to conventional resins. Chromatography has gained a substantial market space in the past few years across several end-use industries concerning its high accuracy and ease of use. Nonetheless, the existence of stringent government regulations and safety standards across food and beverages and pharmaceutical sectors are projected to restrain market growth over the forecast period.Shift in the trend towards the substitution of conventional separation techniques, including distillation and filtration, with chromatography has driven invention for the chromatography applications in several novel segments. The industry is observed to be oligopolistic in nature. The top players account for approximately 65.0% market share across the globe. Other players have a strong foothold over the remaining market share. The pricing and various other strategic initiatives of the market depend on the top market players.North America is anticipated to remain a dominant region in the market over the forecast period. U.S. has been relishing vigorous growth owing to the financial support from the government in the research and development activities. The economic performance of the Asia Pacific region is predicted to observe enhancement, as developing countries, including India and China are expected to ramp up investments in pharmaceutical and chemical sectors. China, which is the prominent consumer in the Asia Pacific market, is estimated to continue its dominance in the near future. India has registered accelerated growth in the past decade due to reforms such as "Make in India" and several financial initiatives, which are expected to encourage domestic manufacturing in the region.Chromatography Resins Market Report Highlights In 2019, natural emerged as the largest type segment, owing to growing demand for agarose, and dextran from several end-use industriesIn 2019, ion exchange emerged as the largest technique segment, due to substantial growth in pharmaceutical sector, especially drug discoverIn 2019, pharmaceutical emerged as the largest end-use segment, concerning upsurge in quality and safety testing of products, coupled with technological advancementDemand for natural resin is growing in several industries on account of its low cost and high functionality, and is anticipated to continue its dominance in the forthcoming years, which will propel the growth of the marketTriAltus Biosciences has developed protein purification technology (novel CL7/Im7 system) to aid providence cancer institute COVID-19 vaccine development. Key Topics Covered: Chapter 1 Methodology And Scope1.1 Market Segmentation & Scope1.2 Market Definition1.3 Information Procurement1.4 Information Analysis1.5 Research Scope And Assumptions1.6 List Of Data Sources1.7 List Of AbbreviationsChapter 2 Executive Summary2.1 Market Snapshot2.2 Segmental Outlook2.3 Competitive InsightsChapter 3 Market Variables, Trends, And Scope3.1 Market Lineage3.2 Penetration & Growth Prospect Mapping, 2016 - 20273.3 Value Chain Analysis3.3.1 Raw Material Trends3.3.2 Manufacturing Trends3.3.3 List Of Key End - User3.4 Regulatory Framework3.5 Technology Overview3.6 Market Dynamics3.6.1 Market Driver Analysis220.127.116.11 High Demand Considering Advances In Drug Development18.104.22.168 Increasing Use Of Chromatography As A Separation Technique In Food & Beverage Industry3.6.2 Market Restraint Analysis22.214.171.124 Costlier Than Other Separation Techniques3.6.3 Industry Challenges3.6.4 Impact Of Covid - 193.7 Business Environment Analysis: Chromatography Resins Market3.7.1 Industry Analysis - Porter's3.7.2 Pestel AnalysisChapter 4 Chromatography Resin Market: Product Estimates & Trend Analysis4.1 Product Movement Analysis, 2019 & 20274.2 Global Chromatography Resin Demand By Product, 2016 - 20274.3 Natural Resins4.4 Synthetic ResinChapter 5 Chromatography Resin Market: Technique Estimates & Trend Analysis5.1 Technique Movement Analysis, 2019 & 20275.2 Global Chromatography Resin Demand By Technique, 2016 - 20275.3 Ion Exchange Resin5.4 Affinity Resin5.5 Hydrophobic Interaction Resin5.6 Size Exclusion Resin5.7 Other Chromatography ResinsChapter 6 Chromatography Resin Market: End - Use Estimates & Trend Analysis6.1 Regional Movement Analysis, 2019 & 20276.2 Global Chromatography Resin Demand By End Use, 2016 - 20276.3 Pharmaceutical6.4 Water & Environmental Agencies6.5 Food & BeverageChapter 7 Chromatography Resin Market: Regional Estimates & Trend AnalysisChapter 8 Competitive Landscape8.1 Vendor Landscape8.2 Competitive Environment8.3 Company Market Positioning8.4 Strategy FrameworkChapter 9 Company Profiles9.1 Company Overview9.2 Financial Performance9.3 Product Benchmarking9.4 Strategic Initiatives Merck KgaaBio - Rad Laboratories, Inc.Thermo Fisher Scientific, Inc.Ge HealthcarePurolite CorporationW. R. Grace & Co.Mitsubishi Chemical CorporationTosoh CorporationDanaher Corporation For more information about this report visit https://www.researchandmarkets.com/r/e4hppf Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Mitchells & Butlers, the company behind All Bar One and the Harvester, Toby Carvery and Browns chains, has revealed it has slashed 1,300 jobs. The FTSE 250 firm which controls more than 1,700 bars, pubs and restaurants, had earlier confirmed it was to close up to 20 sites as a result of the pandemic hit to the hospitality sector. Greene King has axed 800 employees, while Fuller's has made 350 workers redundant.
Though it has a simple purpose, Social Security is a seriously complex government program. In fact, if you were to attempt to read up on all of its rules, you could spend days on the project -- and still not understand all the nuances.
Spirometer Market Research Report by Product Type (Consumables & Accessories, Devices, and Software), by Technology (Flow Measurement, Peak Flow Measurement, and Volume Measurement), by End-User, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19New York, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Spirometer Market Research Report by Product Type, by Technology, by End-User, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05989769/?utm_source=GNW The Global Spirometer Market is expected to grow from USD 724.86 Million in 2019 to USD 1,402.49 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 11.62%.Market Segmentation & Coverage:This research report categorizes the Spirometer to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Product Type, the Spirometer Market studied across Consumables & Accessories, Devices, and Software. The Devices further studied across PC- Based Spirometer, Portable Spirometer, and Table-Top Spirometer. Based on Technology , the Spirometer Market studied across Flow Measurement, Peak Flow Measurement, and Volume Measurement. Based on End-User, the Spirometer Market studied across Homecare Settings, Hospitals and Clinics, and Industrial Settings. Based on Application, the Spirometer Market studied across Asthma, COPD, Cystic Fibrosis, and Pulmonary Fibrosis. Based on Geography, the Spirometer Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Spirometer Market including Cardinal Health, Inc., CHEST M.I., INC., Clarity Medical Pvt. Ltd., Contec Medical Systems Co., Ltd., FUKUDA SANGYO CO., LTD., Fysiomed B.V., Guangzhou Medsinglong Medical Equipment Co. Ltd., Hill-Rom Services, Inc., KONINKLIJKE PHILIPS N.V., Medikro Oy, Medline Industries, Inc., MGC Diagnostics Corporation, Midmark Corporation, ndd Medizintechnik AG, Schiller AG, Semiconductor Physics Laboratory Co. Ltd., Smiths Medical, Inc., Teleflex Incorporated., Vitalograph Ltd., and Vyaire Medical, Inc.. FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Spirometer Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Spirometer Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Spirometer Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Spirometer Market?4. What is the competitive strategic window for opportunities in the Global Spirometer Market?5. What are the technology trends and regulatory frameworks in the Global Spirometer Market?6. What are the modes and strategic moves considered suitable for entering the Global Spirometer Market?Read the full report: https://www.reportlinker.com/p05989769/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
Officials of Ghana's National Democratic Party have condemned as "fake news" the announcement of the withdrawal of party flag bearer, Nana Konadu Agyeman-Rawlings, from next month's presidential election. The announcement of the alleged decision by the widow of Ghana’s first president Jerry Rawlings to withdraw from the contest was reported earlier this week by two major media platforms in Ghana, and reposted by several others.National Democratic Party (NDP) officials have moved to set the record straight.In the wake of ex-president Rawlings' death on 12 November, an Accra-based radio station linked to the National Democratic Congress (NDC), carried the following announcement:“The flag bearer of the National Democratic Party, Nana Konadu Agyeman-Rawlings, has pulled out of the 2020 presidential elections. The last-minute decision is linked to the demise of Konadu’s husband, ex-president Jerry John Rawlings, who died two weeks ago. Reports say the NDP leader has informed the Electoral Commission of her decision." Ghana's former president Jerry Rawlings dies aged 73'Decade of lies'Addressing journalists in the capital Accra, Mohammed Frimpong, NDP National Secretary suggested the announcement was motivated by the NDC’s desperation to salvage the dying political fortunes of its own flag bearer, John Dramani Mahama.Frimpong stressed that the NDP candidate “has not indicated a decision to pull out and has not informed the Electoral Commission” as claimed by the false report.The announcement is the “latest of the lies heaped by the NDC on the Rawlings family over the last decade,” said Mohammed Frimpong.Though he admitted he had not yet spoken to Agyeman-Rawlings, Frimpong dismissed the news of her withdrawal as a “diversion tactic” intended to prevent the NDP from winning the presidential race on 7 December.“The question you should be asking is this: Why is the NDC panicking now over the candidacy of Nana Konadu Agyeman-Rawlings? Why are they afraid now?"It is the ghost of their own misdeeds and marred treatment of the Rawlings and the due reward that awaits them on 7 December, which is haunting the NDC.”Twelve to contest presidential raceMrs Konadu Agyeman-Rawlings is one of twelve candidates cleared by Ghana’s Electoral Commission to contest the 2020 presidential election.Until the demise of her husband, the NDP leader had campaigned vigorously. Agyeman-Rawlings is contesting the presidency for the second time, having been defeated in 2016.The National Democratic Party was founded in the run-up to the 2012 elections following a split with the National Democratic Congress on questions of probity and accountability.Rawlings and the NDCThe relationship has been strained between party founder and former president Rawlings and his party over the last 16 years. There was a sharp and growing misunderstanding between Rawlings, one-term president John Dramani Mahama, and the national executive of the party.Rawlings widely criticised the erstwhile Mahama administration, citing corruption and the absence of accountability to Ghanaians. The former president was consistently critical of the NDC, calling its youthful members “babies with sharp teeth”.Before his demise on 12 November, Rawlings was seen to be living in harmony with the ruling New Patriotic Party, to the detriment of the NDC.A Book of Condolences has been opened at the Accra Conference Centre and has been signed by dignitaries, including the United Nations’ Deputy Secretary General, Amina J. Mohammed, and members of the ECOWAS/AU Pre-Election Mission.The NDC party held a vigil in honour of the founder which was attended by the children of the late president and sympathisers.
Black Friday vacuum deals are here, compare all the best Black Friday & Cyber Monday upright, stick, cordless & robot vacuum cleaners deals below
(Bloomberg) -- Malaysia Prime Minister Muhyiddin Yassin survived a key test of his leadership on Thursday when he won enough support in parliament for his 2021 budget.House Speaker Azhar Azizan Harun determined that the budget was passed in a voice vote. Just 13 lawmakers called for votes to be counted individually, fewer than the 15 required for bloc voting to be held. The results will ensure Muhyiddin, who took power in March, remains in office for now as the budget enters a second round of debates next week.Muhyiddin’s victory on Thursday came after months of pressure on him to prove he commands majority support in parliament. Still, it’s unclear how long he can hang on: His coalition allies have urged him to allow for a confidence motion to be tabled in parliament, and to hold an election once the pandemic is under control.“I was surprised the speaker jumped to a voice vote,” said James Chin, a Malaysian academic and a political analyst who heads the Asia Institute at the University of Tasmania. “We don’t really know what is Muhyiddin’s support on the floor of parliament or the strength of the opposition because no individual vote was taken.”On Thursday, Finance Minister Tengku Zafrul Abdul Aziz sought to offer an olive branch to lawmakers by adding a slew of proposals from both the ruling coalition and opposition parties. The $78 billion spending plan for 2021 is set to be the nation’s biggest budget yet.“We may not be perfect, but we listen,” he said in parliament. “In the coming months, we will continue to listen.”The main equities index closed at its highest level this year, as investors cheered the passage of the budget. The ringgit rose 0.5% to 4.0650, its strongest level against the dollar in 10 months, while sovereign bonds held losses.Opposition leader Anwar Ibrahim said the budget would continue to be scrutinized next week and the opposition would call for individual voting, if necessary.“It’s still too early for them to celebrate excessively,” he said.Muhyiddin had been on shaky ground prior to the vote: In July, he was able to replace the lower house speaker by a majority of just two votes. He had suffered a loss of prestige last month when Malaysia’s king rejected his request to declare a state of emergency to tackle the pandemic, which would’ve allowed him to pass the budget without approval from lawmakers.Losing the budget vote would’ve been unprecedented for a sitting prime minister in Malaysia. Other Westminster parliamentary democracies have established that the defeat of a supply bill amounts to a loss of confidence, Deputy House Speaker Azalina Othman Said wrote on her website.The monarch thanked lawmakers for supporting the budget in parliament, the palace said in a statement.Muhyiddin still faces more challenges in the next few weeks. The supply bill will enter the “committee stage” on Monday, which means several more rounds of voting as the lower house scrutinizes each portion of the bill until it finally adjourns for the year on Dec. 15.If parliament doesn’t agree to a spending plan before the end of this year, only about 20% of the original budget alloted for pensions and debt servicing can be spent without the legislative assembly’s nod, analysts at Maybank wrote in a note.Beyond the budget, the prime minister is also facing increasing pressure from allies to test his support either through an election or in parliament. Motions of confidence filed by various lawmakers have been buried at the bottom of the order paper due to government matters taking precedence.“The government should make it a priority to bring a motion of confidence into this noble house,” said UMNO president Ahmad Zahid Hamidi, the head of a key ruling coalition ally, during the budget debate last week. “The mandate comes from the people, so the mandate should be returned to the people.”(Adds opposition leader’s comment in eighth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
These are the big savings to take advantage of, from headphones to fitness trackers
The monster movie may premiere on HBO Max
Save up to 50% on a brand new pair of Oakley sunglasses this Black Friday
Constantly exhausted? Look out for these telltale signs that something serious is amiss.
New restrictions come into force on 2 December
Dublin, Nov. 26, 2020 (GLOBE NEWSWIRE) -- The "Pharmacovigilance Market Size, Share & Trends Analysis Report by Product Life Cycle, by Service Provider, by Type, by Therapeutic Area, by Process Flow, by End-use, and Segment Forecasts, 2020-2027" report has been added to ResearchAndMarkets.com's offering. Phase IV held a dominant market share at 75.56% in 2019 owing to the extensive post-marketing surveillance of pharmaceuticals and an increasing number of ADR incidences in the marketADR imposes a substantial burden on healthcare systems and is one of the prominent causes of morbidity in developed countries. According to the National Center for Biotechnology Information (NCBI), approximately 5% of total hospitalizations in Europe each year, are due to ADR. Pharmacovigilance services play an integral role in this clinical trial phase by assisting manufacturers in identifying adverse effects associated with the drug.According to the World Health Organization's (WHO) report on pharmaceutical consumption, medicines to treat chronic diseases accounted for a larger proportion of the total volume of drug consumption in non-hospital setups. Hence, there has been a significant rise in the number of medicines made available to healthcare consumers. Rising demand for drugs has significantly heightened the need for the development of novel therapeutics via extensive clinical trials, which is expected to serve this market with lucrative opportunities.Moreover, leading pharma companies in developed countries are focusing on outsourcing PV services to reduce cost and to minimize operational expenses. This is anticipated to serve as an opportunity for contact research organizations in developing regions to gain more revenue share. Manufacturers are now focusing on remodeling their product development processes in an attempt to cater to patient needs across the globe. These factors are anticipated to fuel the demand for pharmacovigilance services during the forecast period.The companies operating in the pharmacovigilance market are undertaking strategic initiatives, such as collaborations with the PV service providers to gain access to medical information and to manage PV workflows. For instance, in September 2019, Accenture collaborated with Bayer to implement the company's INTIENT Clinical platform to simplify and speed its drug development processes, thereby widening business. The company collaborated with BioCelebrate in 2017 to develop a platform for aggregating and analyzing clinical information for improved drug developing efficiency, thus enhancing its R&D capabilities. Such initiatives help companies maintain their market position.Pharmacovigilance Market Report Highlights In the service provider segment, contract outsourcing held a significant market share of around 57% as of 2019, owing to the shift in focus of pharmaceutical companies to outsourcing services to reduce operational costBased on types, spontaneous reporting held the largest revenue share due to its wide application in pharmacovigilance and benefits such as easy simulation of data sets for better drug comparisonThe biotechnology segment is anticipated to exhibit a lucrative CAGR of 13.9% over the forecast period owing to increasing R&D for the development of novel biologicsAsia Pacific is anticipated to showcase a lucrative CAGR of 14.9% in the forthcoming years. This is attributing to the availability of low-cost labor and the rising number of outsourcing companies in this regionIndustry participants are focusing on increasing R&D activities to develop better pharmacovigilance services. Moreover, companies are adopting strategies including new product launch, collaborations, and mergers & acquisitions to gain a competitive advantage Key Topics Covered: Chapter 1 Research Methodology & ScopeChapter 2 Executive SummaryChapter 3 Pharmacovigilance Market Variables, Trends & Scope3.1 Market Lineage Outlook3.1.1 Parent market analysis3.1.2 Ancillary market Analysis3.2 Penetration & Growth Prospect Mapping3.3 Pharmacovigilance Market Dynamics3.3.1 Market driver analysis126.96.36.199 Growing drug consumption and drug development rates188.8.131.52 Increasing incidence of ADR and drug toxicity184.108.40.206 Increasing trend of outsourcing pharmacovigilance services220.127.116.11 Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies18.104.22.168 Increasing regulatory burden on manufacturers22.214.171.124 Introduction of technologically advanced software services126.96.36.199 Constantly rising investment on R&D by healthcare companies188.8.131.52 Partnerships and collaborations between market players3.3.2 Market restraint analysis184.108.40.206 Shortage of skilled labor220.127.116.11 Expensive technology for small and mid-sized player18.104.22.168 Lack of recognition22.214.171.124 Scarcity of integration standards3.3.3 Industry Challenges3.4 Pharmacovigilance Market Analysis Tools: Porters3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)3.6 Value Chain Analysis3.6.1 Preclinical3.6.2 Clinical3.6.3 PMA3.7 Mapping of Life Cycle Against Service Offering and Their Demand3.8 Regulatory Framework3.8.1 List of regulatory bodies by Country3.9 Pharmacovigilance: Organization Structure Introduction3.10 Pricing Models3.10.1 Drug Safety Budget Allocation By Activities3.10.2 By Development phase3.10.3 By Therapeutic area3.10.4 Pricing Level126.96.36.199 Case processing188.8.131.52 ADR Reporting184.108.40.206 Medical writing220.127.116.11 Drug safety management3.11 Technology Timeline Overview3.11.1 Changing Technology & Adoption18.104.22.168 Social Media22.214.171.124 Literature screening126.96.36.199 Automation and AI188.8.131.52 Big data analytics in PVChapter 4 COVID-19 Impact Analysis4.1 COVID-19 Outbreak4.1.1 Challenges for safety reporting activities4.2 Demand Analysis4.2.1 Product Pipeline Analysis, by Stage for COVID-194.3 Recent Developments & Strategic Outcomes4.3.1 Regulatory requirements/changes due to covid-194.3.2 Strategies implemented by companies184.108.40.206 IQVIA220.127.116.11 PARAXEL International Corporation18.104.22.168 Bioclinica22.214.171.124 Pharmaceutical Product Development (PPD)126.96.36.199 IBM Corporation188.8.131.52 ICON, plc184.108.40.206 PRA Health Sciences220.127.116.11 Covance Inc18.104.22.168 ArisGlobal22.214.171.124 Linical Accelovance126.96.36.199 Laboratory Corporation of America HoldingsChapter 5 Pharmacovigilance Market: Service provider Estimates & Trend Analysis5.1 Service Provider Market Share Analysis, 2019 & 20275.2 Service Provider Dashboard5.2.1 In House5.2.2 Contract OutsourcingChapter 6 Pharmacovigilance Market: Type Estimates & Trend Analysis6.1 Type Market Share Analysis, 2019 & 20276.2 Type Dashboard6.2.1 Spontaneous Reporting6.2.2 Intensified ADR Reporting6.2.3 Targeted Spontaneous Reporting6.2.4 Cohort Event Monitoring (CEM)6.2.5 EHR MiningChapter 7 Pharmacovigilance Market: Product Life Cycle Estimates & Trend Analysis7.1 Product Life Cycle Market Share Analysis, 2019 & 20277.2 Product Dashboard7.2.1 Preclinical7.2.2 Phase I7.2.3 Phase II7.2.4 Phase III7.2.5 Phase IVChapter 8 Pharmacovigilance Market: Process Flow Estimates & Trend Analysis8.1 Process Flow Market Share Analysis, 2019 & 20278.2 Process Flow Dashboard8.2.1 Case data management8.2.2 Signal detection8.2.3 Risk Management SystemChapter 9 Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis9.1 Therapeutic Area Market Share Analysis, 2019 & 20279.2 Therapeutic Area Dashboard9.2.1 Oncology9.2.2 Neurology9.2.3 Cardiology9.2.4 Respiratory systemsChapter 10 Pharmacovigilance Market: End-Use Estimates & Trend Analysis10.1 End-Use Market Share Analysis, 2019 & 202710.2 End-Use Dashboard10.2.1 Pharmaceuticals10.2.2 Biotechnology Companies10.2.3 Medical Device ManufacturersChapter 11 Pharmacovigilance Market: Regional Estimates & Trend Analysis by SegmentsChapter 12 Competitive Outlook12.1 Market Participation Categorization12.2 Public Companies12.2.1 Company market position analysis12.2.2 Company Market Share12.3 Private Companies12.3.1 List of key emerging companies12.4 Consolidation Trends12.5 Potential CustomersChapter 13 Company Profiles13.1 Company overview13.2 Service benchmarking13.3 Organization structure & Team Composition13.3.1 Team composition13.4 Financial performance13.5 R&D expenditure13.6 Strategic initiatives13.7 SWOT Analysis AccentureClinquest Group B.V. (Linical Americas)IQVIACognizantLaboratory Corporation of America HoldingsIBM CorporationArisGlobalICON Plc.CapgeminiITClinicalTAKE SolutionsPAREXEL International CorporationBioClinica, Inc.Wipro LimitedUNITED BIOSOURCE CORPORATIONFMD K&L For more information about this report visit https://www.researchandmarkets.com/r/7r464n Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The Semiconductor Market will grow by USD 90.80 bn during 2020-2024